Publication for MAGEA1 and MAGEC1

Species	Symbol	Function*	Entrez Gene ID*	Other ID	Gene coexpression	CoexViewer
hsa	MAGEA1	MAGE family member A1	4100			[link]
hsa	MAGEC1	MAGE family member C1	9947

Pubmed ID	Priority	Text
23145101	0.98	MAGEA1, MAGEA3, MAGEA6, MAGEC1, MAGEC2, and PTTG1) and transcripts important in regulating development (HOXB7, HOXB8, HOXB9, NANOGNB, and LOC404266).
	0.93	MAGEA1, MAGEC1, MAGEC2, CTAGB1, BIRC5, and TOP2A.
23666534	0.98	MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10, SSX1, SSX2, SSX4, SOX2, CT7, CT10, CT45, CT46, CT47, XAGE-1, GAGE2, PASD1, CSAG2, TRAG3, ERG, NXF2, SAGE1, ACTL8, CXorf48, UBQLN2, or DHFR (data not shown).
24427779	0.98	MAGE-1, MAGE-3, MAGE-4, MAGE-10, MAGE-B1, MAGE-B2, MAGE-C1, MAGE-C2, NY-ESO-1 or other CT antigens were highly expressed in the tumor tissue of Chinese HCC patients.
29856138	0.98	MAGE-A1, MAGE-A3, MAGEH1, MAGE-A9, MAGE-C1/CT7, and MAGE-C2/CT10) and NY-ESO-1, the most prevalently expressed antigens in spontaneous humoral to mediate T cell responses, has been described in tumor patients.24, 25, 26, 27, 28 Shida et al14 reported that CT83 expression was observed in gastric cancer, while the frequency of CT83 expression (81.6%) was higher than that of the MAGE-A1 (34.7%), MAGE-A3 (44.9%), and NY-ESO-1(16.3%).
26057582	0.97	MAGE-A1 (P=0.034) and MAGE-C1 (P=0.008) in patients with HBV infection compared with patients without HBV infection, while MAGE-C2 (P=0.264) and GPC-3 (P=0.334) showed a statistical trend towards higher expression in patients with HBV infection (Figure 3).
	0.97	MAGE-A1, MAGE-A3/4 and MAGE-C1 expression in HBV-positive patients.
	0.93	MAGE-A1, MAGE-A3/4, MAGE-A10, MAGE-C1, MAGE-C2, NY-ESO-1, Sperm Protein 17 (SP17) and SSX-2, the oncofetal proteins AFP and Glypican-3 (GPC-3), the overexpressed tumour antigens Annexin-A2, Wilms tumour-1 (WT-1), Survivin, Midkine (MDK) and the glycoprotein MUC-1.
20862285	0.96	MAGEA1, MAGEA4, MAGEC1, MAGEC2, as well as the genes for the ubiquitously expressed MAGEE1 (also encoded on the X chromosome) in breast and brain tumors.
	0.95	MAGEA1, MAGEA4, MAGEC1, MAGEC2, MAGEE1).
	0.62	MAGEA1 to 16% in MAGEC1.
30062133	0.96	MAGE A1, MAGE A3, MAGE A4, MAGE C1/CT7, and MAGE C2/CT10) was performed.
	0.96	MAGE-A1, MAGE-C1/CT7, MAGE-C2/CT10, and NY-ESO1 did not show any correlation with outcome.7, 27, 28 A prognostic relevance could be attributed to three of the CTA, which were analyzed in our study: MAGE-A1, MAGE-C1, and MAGE-A4.
	0.92	MAGE-A1, and MAGE-C1/CT7.
23935846	0.96	MAGE-A1, MAGE-A4 and MAGE-C1 expression and survival in the BR.10 study.
	0.94	MAGE-A1, MAGE-A4 and MAGE-C1 could be mapped to the array, NY-ESO-1 was not present after mapping to modern gene-annotations.
16479255	0.96	MAGE-1, MAGE-3, NY-ESO-1, and CT7 are frequently found in only a small proportion of cancer tissues (Jungbluth et al, 2000, 2002), an indication that the cancers contain both stem cells and differentiated cells (Simpson et al, 2005).
25101620	0.94	MAGE-A1, MAGE-A10, MAGE-C1 and other known clinico-pathologic prognostic factors in ovarian cancer.
	0.86	MAGE-C1 expression, was diminished by co-expression of MAGE-A1 or -A10.
20108890	0.93	MAGE-A1, multiple MAGE-A family members, SSX1, and CT7) served as positive controls (Figure 3A).
	0.67	CT7; C4, NY-ESO-1, SSX1, and MAGE-A1.
30038519	0.77	MAGEA1 (no or unknown mutant status vs mutant, 62.0% vs 87.5%, P=0.253), MAGEA3 (33.7% vs 37.5%, P=1.000), MAGEA10 (62.0% vs 50.0%, P=0.708), MAGEB2 (26.1% vs 37.5%, P=0.443), MAGEC1 (61.9% vs 75.0%, P=0.707), XAGE1 (47.8% vs 62.5%, P=0.483), KK-LC-1 (45.7% vs 75.0%, P=0.149), CTAG1A/B (50.0% vs 50.0%, P=1.000), VCX1 (23.9% vs 25.0%, P=1.000), and VCX3A (26.1% vs 0.0%, P=0.193).
	0.65	MAGEC1, KK-LC-1, MAGEA10, and MAGEA1, range 25.5%-60.0% (Figure 2A).
32133047	0.67	MAGE-A1, A3, A4, and A6, reflecting the high degree of sequence homology and potentially shared functions among MAGE-A, but MAGE-C1 was not affected.
31516568	0.66	MAGEA1 (HR, 0.81; 95% CI, 0.71-0.91; P=0.0005), MAGEA4 (HR, 0.84; 95% CI, 0.75-0.93; P=0.0012), MAGEA5 (HR, 0.79; 95% CI, 0.71-0.88; P=2.5x10-5), MAGEA6 (HR, 0.87; 95% CI, 0.77-0.98; P=0.0200), MAGEA8 (HR, 0.71; 95% CI, 0.63-0.79; P=4.0x10-10), MAGEA9 (HR, 0.82; 95% CI, 0.72-0.93; P=0.0016), MAGEA10 (HR, 0.63; 95% CI, 0.56-0.71; P=3.7x10-15), MAGEA11 (HR, 0.80; 95% CI, 0.71-0.90; P=0.0003), MAGEA12 (HR, 0.79; 95% CI, 0.70-0.89; P=8.7x10-5) (Fig. 1B-1/4/5/6/8/9/10/11); MAGEB1 (HR, 0.82; 95% CI, 0.74-0.92; P=0.0005), MAGEB2 (HR, 0.68; 95% CI, 0.61-0.76; P=6.8x10-12), MAGEB3 (HR, 0.83; 95% CI, 0.74-0.93; P=0.0017), MAGEB4 (HR, 0.84; 95% CI, 0.73-0.95; P=0.0058), MAGEB6 (HR, 0.78; 95% CI, 0.65-0.92; P=0.0031), MAGEC1 (HR, 0.72; 95% CI, 0.64-0.82; P=2.2x10-7), MAGEC2 (HR, 0.67; 95% CI, 0.60-0.75; P=6.7x10-13), MAGEC3 (HR, 0.76; 95% CI, 0.68-0.86; P=7.5x10-6), MAGED2 (HR, 0.78; 95% CI, 0.69-0.87; P=3.1x10-5), MAGED3 (HR, 0.82; 95% CI, 0.74-0.92; P=0.0009), MAGEE1 (HR, 0.73; 95% CI, 0.62-0.86; P=8.7x10-5), MAGEF1 (HR, 0.76; 95% CI, 0.67-0.85; P=4.2x10-6) and MAGEL2 (HR, 0.77; 95% CI, 0.68-0.87; P=4.3x10-5) (Fig. 1C-1/2/3/4/5/7/8/9/11/12/14/16/18) were observed to be significantly associated with better prognosis.
25914874	0.60	MAGE-1, MAGE-3, MAGE-C2, MAGE-C1, MAGE-A1, MAGE-A3, PRAME, NY-ESO-1, SSX1, SSX4, SSX5, SSX2, BAGE, ADAM2, LIPI, Dickkof-1, hTERT, CD138, XBP1, CS1, WT1, survivin, and BCMA.